Roughly 40 percent of adults in Spain are overweight and about 15 percent are obese, figures that keep obesity at the center of the country's public health debate. The World Health Organization describes the condition as a major public health problem, and the scale of the figures explains why it has moved from the clinic into everyday conversation, from pharmacy counters to social media feeds.
Much of that conversation now takes place online. Platforms promote restrictive diets and so-called miracle products, often with little information about who stands behind the advice. Experts warn that the sheer volume of content can overwhelm readers, making it harder to separate evidence-based guidance from marketing. Checking the identity and credentials of whoever is offering advice is, in their view, a basic safeguard for anyone trying to lose weight.
The most visible shift in recent years has come from drugs. Ozempic, with the active ingredient semaglutide, was approved to treat diabetes but has become widely used for weight loss, a use that has reshaped the market. Novo Nordisk, its manufacturer, became Europe's most valuable company in 2023. The same molecule is sold as Wegovy, which is approved specifically for obesity. Eli Lilly's Mounjaro, based on tirzepatide, has also shown good results in trials and is part of the same fast-growing category.
The financial side of the issue is notable. Ozempic is, according to the reporting, Spain's most publicly funded drug, accounting for about 3 of every 100 euros spent on medicines through public financing. Weight-loss drugs, by contrast, require a prescription and are not publicly funded, so patients who want them typically pay themselves. The monthly cost can exceed 200 euros, a sum that puts the treatments out of reach for many households and raises questions about access and equity.
Manufacturers are also looking to broaden the options. Novo has presented an oral version of Wegovy, a pill that the company reports can produce weight loss of up to 17 percent when combined with lifestyle changes. The development points to a market in which treatment may increasingly move from injections to tablets, though the figures reflect company-reported results rather than independent verdicts on long-term outcomes.
For readers navigating this landscape, the practical lesson from specialists is caution. Prescription medicines should be discussed with a qualified doctor, and advice found on social media deserves scrutiny regarding its source. As obesity remains widespread across the country, the combination of online influence, high-priced drugs and the absence of public coverage for weight-loss treatments is likely to keep the issue at the center of Spanish health policy debates.